AIM: Capecitabine is an oral fluoropyrimidine that can effectively replace infusional 5-fluorouracil (5-FU) for treatment of colorectal, gastric and breast cancer. This study aims to analyze the incidence and the relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-FU in randomized clinical trials (RCTs). METHODS: MEDLINE and Cochrane Library were reviewed for RCTs that compared capecitabine with 5-FU for treatment of solid malignancies. The incidence and relative risk (RR) of grade 3/4 diarrhoea were estimated for each arm in the overall population and in colorectal cancer (CRC) patients RESULTS: Twenty-three studies and 15,761 patients were included. Among these 8303 and 7458 patients received capecitabine or 5-FU based therapies, respectively. In the overall populations severe diarrhoea was reported in 16.6% (95% CI 15.8, 17.4) and in 12.7% (95% CI 11.9, 13.4) of patients treated with capecitabine or 5-FU-based therapies, respectively. The RR was 1.39 (95% CI 1.14, 1.69, P = 0.0010). In 14,899 CRC patients, the incidence of severe diarrhoea was 17.0% (95% CI 16.2, 17.9) and 12.9% (95% CI 12.1, 13.7), respectively, with a RR of 1.46 (95% CI 1.18, 1.81, P < 0.0001). In CRC patients treated with combined chemotherapy, the RR was 1.40 (95% CI 1.07, 1.82; P = 0.01) for patients receiving oxaliplatin and 2.35 (95% CI 1.76, 3.13; P < 0.0001) for patients receiving irinotecan. CONCLUSIONS: Treatment with capecitabine is characterized by an increased risk of severe diarrhoea, mainly in patients affected by CRC and treated with polichemotherapy. Combination treatment with irinotecan doubles the risk over 5-FU.
AIM: Capecitabine is an oral fluoropyrimidine that can effectively replace infusional 5-fluorouracil (5-FU) for treatment of colorectal, gastric and breast cancer. This study aims to analyze the incidence and the relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-FU in randomized clinical trials (RCTs). METHODS: MEDLINE and Cochrane Library were reviewed for RCTs that compared capecitabine with 5-FU for treatment of solid malignancies. The incidence and relative risk (RR) of grade 3/4 diarrhoea were estimated for each arm in the overall population and in colorectal cancer (CRC) patients RESULTS: Twenty-three studies and 15,761 patients were included. Among these 8303 and 7458 patients received capecitabine or 5-FU based therapies, respectively. In the overall populations severe diarrhoea was reported in 16.6% (95% CI 15.8, 17.4) and in 12.7% (95% CI 11.9, 13.4) of patients treated with capecitabine or 5-FU-based therapies, respectively. The RR was 1.39 (95% CI 1.14, 1.69, P = 0.0010). In 14,899 CRCpatients, the incidence of severe diarrhoea was 17.0% (95% CI 16.2, 17.9) and 12.9% (95% CI 12.1, 13.7), respectively, with a RR of 1.46 (95% CI 1.18, 1.81, P < 0.0001). In CRCpatients treated with combined chemotherapy, the RR was 1.40 (95% CI 1.07, 1.82; P = 0.01) for patients receiving oxaliplatin and 2.35 (95% CI 1.76, 3.13; P < 0.0001) for patients receiving irinotecan. CONCLUSIONS: Treatment with capecitabine is characterized by an increased risk of severe diarrhoea, mainly in patients affected by CRC and treated with polichemotherapy. Combination treatment with irinotecan doubles the risk over 5-FU.
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem Journal: Ann Oncol Date: 2007-12-06 Impact factor: 32.976
Authors: Pasquale Comella; Bruno Massidda; Gianfranco Filippelli; Antonio Farris; Donato Natale; Giuseppe Barberis; Luigi Maiorino; Sergio Palmeri; Michele Cannone; Giovanni Condemi Journal: J Cancer Res Clin Oncol Date: 2008-08-22 Impact factor: 4.553
Authors: Y-K Kang; W-K Kang; D-B Shin; J Chen; J Xiong; J Wang; M Lichinitser; Z Guan; R Khasanov; L Zheng; M Philco-Salas; T Suarez; J Santamaria; G Forster; P I McCloud Journal: Ann Oncol Date: 2009-01-19 Impact factor: 32.976
Authors: M L Rothenberg; J V Cox; C Butts; M Navarro; Y-J Bang; R Goel; S Gollins; L L Siu; S Laguerre; D Cunningham Journal: Ann Oncol Date: 2008-06-10 Impact factor: 32.976
Authors: Frank Daniel Martos-Benítez; Andrés Soto-García; Anarelys Gutiérrez-Noyola Journal: J Cancer Res Clin Oncol Date: 2018-01-23 Impact factor: 4.553
Authors: Jae-Seok Min; Chang Min Lee; Sung Il Choi; Kyung Won Seo; Do Joong Park; Yong Hae Baik; Myoung-Won Son; Won Hyuk Choi; Sungsoo Kim; Kyung Ho Pak; Min Gyu Kim; Joong-Min Park; Sang Ho Jeong; Moon-Soo Lee; Sungsoo Park Journal: J Gastric Cancer Date: 2018-09-07 Impact factor: 3.720
Authors: Vincenzo De Falco; Maria Iole Natalicchio; Stefania Napolitano; Nicola Coppola; Giovanni Conzo; Erika Martinelli; Nicoletta Zanaletti; Pasquale Vitale; Emilio Francesco Giunta; Maria Teresa Vietri; Pietro Paolo Vitiello; Davide Ciardiello; Anna Marinaccio; Ferdinando De Vita; Fortunato Ciardiello; Teresa Troiani Journal: Medicine (Baltimore) Date: 2019-05 Impact factor: 1.817